Literature DB >> 9858442

Pentosidine in synovial fluid in osteoarthritis and rheumatoid arthritis: relationship with disease activity in rheumatoid arthritis.

J R Chen1, M Takahashi, M Suzuki, K Kushida, S Miyamoto, T Inoue.   

Abstract

OBJECTIVE: Pentosidine is an advanced glycation endproduct formed by glycosylation and oxidation. Our aim was to develop a means to measure pentosidine in synovial fluid (SF), and to compare its concentration in SF in patients with osteoarthritis (OA) and rheumatoid arthritis (RA), and to investigate the relationship between its concentration in SF and the disease activity of RA.
METHODS: SF was collected from knee joints in 31 patients with RA and 40 with OA, who had hydrarthrosis. One patient with RA and 7 with OA who had the complication of diabetes mellitus or chronic renal failure made up the DM/CRF group, and the remaining patients made up the RA group (n = 30) and the OA group (n = 33). Pentosidine was measured by the direct HPLC method with column switching after hydrolysis of SF.
RESULTS: Pentosidine was detected in all SF and was greater in RA (83.9 +/- 46.0 nmol/l, mean +/- SD) than in OA (40.1 +/- 19.6 nmol/l). Three DM/CRF patients undergoing hemodialysis had markedly high pentosidine levels (482.5 +/- 280.8 nmol/l). There was a significant correlation between pentosidine and C-reactive protein (CRP), erythrocyte sedimentation rate, and Lansbury Index (p < 0.01). Patients with RA were divided into high and low activity groups according to the CRP and Lansbury Index. Pentosidine was significantly higher in the high activity group (CRP > or = 2.0 mg/dl and Lansbury Index > or = 50%) than in the low activity group (CRP < 2.0 and/or Lansbury Index < 50) (100.9 +/- 42.8 vs 58.5 +/- 39.6 nmol/; p = 0.0013).
CONCLUSION: Pentosidine in synovial fluid was higher in RA than in OA. Pentosidine levels in SF were related to the disease activity in RA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9858442

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure.

Authors:  Morten A Karsdal; Mette J Nielsen; Jannie M Sand; Kim Henriksen; Federica Genovese; Anne-Christine Bay-Jensen; Victoria Smith; Joanne I Adamkewicz; Claus Christiansen; Diana J Leeming
Journal:  Assay Drug Dev Technol       Date:  2012-10-09       Impact factor: 1.738

2.  Pentosidine in osteoarthritis: HPLC determination in body fluids and in tissues.

Authors:  Pavel Spacek; Milan Adam
Journal:  Rheumatol Int       Date:  2006-03-31       Impact factor: 2.631

3.  Increased pentosidine, an advanced glycation end product, in serum and synovial fluid from patients with knee osteoarthritis and its relation with cartilage oligomeric matrix protein.

Authors:  L Senolt; M Braun; M Olejárová; S Forejtová; J Gatterová; K Pavelka
Journal:  Ann Rheum Dis       Date:  2005-06       Impact factor: 19.103

Review 4.  Advanced glycation endproducts and osteoarthritis.

Authors:  Deborah M Saudek; Jonathan Kay
Journal:  Curr Rheumatol Rep       Date:  2003-02       Impact factor: 4.686

5.  Pentosidine, an advanced glycation end-product, may reflect clinical and morphological features of hand osteoarthritis.

Authors:  Martin Braun; Hana Hulejová; Jindřiška Gatterová; Mária Filková; Andrea Pavelková; Olga Sléglová; Nikola Kaspříková; Jiří Vencovský; Karel Pavelka; Ladislav Senolt
Journal:  Open Rheumatol J       Date:  2012-06-01

6.  Advanced glycation end-product (AGE)-damaged IgG and IgM autoantibodies to IgG-AGE in patients with early synovitis.

Authors:  Marianna M Newkirk; Raphaela Goldbach-Mansky; Jennifer Lee; Joseph Hoxworth; Angie McCoy; Cheryl Yarboro; John Klippel; Hani S El-Gabalawy
Journal:  Arthritis Res Ther       Date:  2003-01-06       Impact factor: 5.156

Review 7.  Receptor for advanced glycation end products and its involvement in inflammatory diseases.

Authors:  Yaw Kuang Chuah; Rusliza Basir; Herni Talib; Tung Hing Tie; Norshariza Nordin
Journal:  Int J Inflam       Date:  2013-09-11

8.  Transition of healthy to diseased synovial tissue in rheumatoid arthritis is associated with gain of mesenchymal/fibrotic characteristics.

Authors:  Marjan M C Steenvoorden; Tanja C A Tolboom; Gabri van der Pluijm; Clemens Löwik; Cornelis P J Visser; Jeroen DeGroot; Adriana C Gittenberger-DeGroot; Marco C DeRuiter; Bert J Wisse; Tom W J Huizinga; René E M Toes
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

9.  Serum and bone pentosidine in patients with low impact hip fractures and in patients with advanced osteoarthritis.

Authors:  Jan Vaculík; Martin Braun; Pavel Dungl; Karel Pavelka; Jan J Stepan
Journal:  BMC Musculoskelet Disord       Date:  2016-07-22       Impact factor: 2.362

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.